Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (DE:JNJ)
XETRA:JNJ
Johnson & Johnson (JNJ) Stock Price & Analysis
129 Followers
JNJ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€132.78 - €161.20
Previous Close€146.96
Volume14.00
Average Volume (3M)3.24K
Market Cap
€353.84B
Enterprise Value€368.54B
Total Cash (Recent Filing)$25.48B
Total Debt (Recent Filing)$41.49B
Price to Earnings (P/E)23.0
Beta0.02
Next Earnings
Oct 15, 2024EPS Estimate
€2.03Next Dividend Ex-Date
Aug 27, 2024Dividend Yield3.08%
Share Statistics
EPS (TTM)6.40
Shares Outstanding2,406,679,183
10 Day Avg. Volume2,875
30 Day Avg. Volume3,242
Standard Deviation0.05
R-Squared0.09
Alpha0.00456
Financial Highlights & Ratios
Price to Book (P/B)-405.89
Price to Sales (P/S)3.92
Price to Cash Flow (P/CF)24.50
P/FCF Ratio30.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.26
Enterprise Value/Gross Profit6.29
Enterprise Value/Ebitda18.40
Forecast
1Y Price Target
€159.46Price Target Upside7.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Johnson & Johnson News
Bulls Say, Bears Say
Bulls Say
Earnings And RevenueSecond-quarter revenue was $22.45B, reflecting 6.5% adjusted operational growth, which topped the consensus estimate of $22.32B.
Growth ProspectsJNJ delivered a solid 2Q driven by Pharma outperformance due to strong growth by Oncology and I&I franchises.
Innovative MedicineAdjusted operational revenue growth for Innovative Medicine was 9.0%, and the division returned its first-ever quarter with more than $14B in sales.
Bears Say
EarningsLowering near-term EPS to reflect deal-related dilution.
LitigationUncertainties on talc litigation and longer-term pipeline keep analysts on the sidelines.
Sales GrowthJNJ expects Innovative Medicine sales growth to be lower due to the anticipated biosimilar entry of Stelara in Europe.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.20% Insiders
18.66% Mutual Funds
24.19% Other Institutional Investors
56.95% Public Companies and
Individual Investors
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was €132.78 and its highest was €161.20 in the past 12 months.
What is Johnson & Johnson’s market cap?
Currently, no data Available
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Oct 15, 2024 which is in 80 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Jul 17, 2024. The company reported €2.589 earnings per share for the quarter, beating the consensus estimate of €2.489 by €0.1.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of €1.14 which represents an annual dividend yield of 3.08%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is €2.03.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,406,679,200 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of €2.589 in its last earnings report, beating expectations of €2.489. Following the earnings report the stock price went up 3.347%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Among the largest hedge funds holding Johnson & Johnson’s share is Fisher Asset Management LLC. It holds Johnson & Johnson’s shares valued at 1B.
---
Johnson & Johnson Stock Smart Score
Company Description
Johnson & Johnson
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
---
JNJ Company Deck
---
JNJ Earnings Call
Q2 2024
0:00 / 0:00
---
JNJ Sales Breakdown
64.30% Innovative Medicine
35.70% MedTech
---
JNJ Stock 12 Month Forecast
Average Price Target
€159.46
▲(7.52% Upside)
Technical Analysis
Johnson & Johnson
―
Pfizer
―
Merck & Company
―
Abbott Laboratories
―
Bristol-Myers Squibb
―
Best Analysts Covering JNJ
1 Year
1 Year Success Rate
22/23 ratings generated profit
1 Year Average Return
+9.32%
reiterated a buy rating 2 months ago
Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +9.32% per trade.
---